Diabetes care is incredibly complex and people are still trying to use data to predict issues with glycemic control, determine what the best combinations of drugs are, and to improve adherence with patients, explained Lonny Reisman, MD, CEO of HealthReveal and keynote speaker at Patient-Centered Diabetes Care.
Diabetes care is incredibly complex and people are still trying to use data to predict issues with glycemic control, determine what the best combinations of drugs are, and to improve adherence with patients, explained Lonny Reisman, MD, CEO of HealthReveal and keynote speaker at Patient-Centered Diabetes Care.
Transcript (slightly modified)
How does diabetes care benefit from the use of big data?
I think diabetes care is complex in many ways. There’s clearly an emphasis on glycemic control and, to the extent that there are risks to hypoglycemia, we’re learning, for example—there’s collaboration between Medtronic and IBM Watson—we’re learning how to predict hypoglycemia in patients at risk. There are certainly issues with poor glycemic control, severe hyperglycemia, and control of A1C.
So, again, understanding what combinations of drugs work, patient preferences, where the evidence is compelling regarding other benefits of certain drugs; Jardiance is an example where we’ve seen cardiovascular outcomes improved in well-conducted trials. So there’s just so much that we can do regarding what’s effective, learning what patients are willing to do or need to do in order to improve adherence and behavior.
Diabetes obviously is a critically important disease, with difficult and sometimes tragic complications, so I think we’re all highly motivated to do what we can to help that population.
How Pharmacy Deserts, Biosimilars, and Market Trends Are Shaping Managed Care
April 2nd 2025Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in managed care, creating both challenges and opportunities for stakeholders, as explored by speakers at the Academy of Managed Care Pharmacy’s annual meeting.
Read More
Areas of Unmet Need Continue to Burden Patients With gMG
April 2nd 2025Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those treating and being treated for the chronic autoimmune neuromuscular disorder, to have a more nuanced understanding of experiences and difficulties.
Read More